Immune-mediated hemolytic anemia and severe thrombocytopenia in dogs: 12 cases (2001–2008)

Authors

  • Elizabeth S. Orcutt DVM, MS,

    1. Section of Small Animal Internal Medicine, C339 Veterinary Medical Center, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108-6192
    Search for more papers by this author
  • Justine A. Lee DVM, DACVECC,

    1. Section of Emergency and Critical Care, C339 Veterinary Medical Center, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108-6192
    2. Department of Clinical Sciences, C339 Veterinary Medical Center, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108-6192
    Search for more papers by this author
  • Domenico Bianco DVM, PhD, DACVIM

    1. Section of Small Animal Internal Medicine, C339 Veterinary Medical Center, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108-6192
    Search for more papers by this author

  • This work was completed at the Veterinary Medical Center, College of Veterinary Medicine, University of Minnesota, St Paul, MN in 2008.

  • The authors declare no conflict of interest.

  • Dr. Lee's current address: Pet Poison Helpline, 8009 34th Avenue South, Ste 875, Bloomington, MN 55425.

  • Dr. Bianco's current address: Red Bank Veterinary Hospital, 197 Hance Ave, Tinton Falls, NJ 07724.

Address correspondence and reprint requests to
Dr. Elizabeth Orcutt, Section of Small Animal Internal Medicine, Department of Clinical Sciences, C339 Veterinary Medical Center, College of Veterinary Medicine, University of Minnesota, 1352 Boyd Ave, St Paul, MN 55108-6192, USA. Email: orcut015@umn.edu

Abstract

Objective – To identify and characterize the syndrome of immune-mediated hemolytic anemia (IMHA) with concurrent severe thrombocytopenia (≤15.0 × 109 platelets/L; [15.0 × 103 platelets/μL]), and to evaluate prognostic factors, clinicopathologic findings, complications, treatment, outcome, and survival of dogs with this hematologic disorder.

Design – Retrospective, observational study.

Setting – Veterinary teaching hospital.

Animals – Twelve client-owned dogs with IMHA and severe thrombocytopenia (≤15.0 × 109 platelets/L; [15.0 × 103 platelets/μL]), without evidence of overt disseminated intravascular coagulation.

Interventions – The following data were recorded and analyzed from the electronic medical record: signalment, history, concurrent diseases, clinical signs at presentation, clinicopathologic data, diagnostic testing, radiographic findings, treatment modalities, length of hospitalization, complications, and clinical outcome. All dogs were treated with immunosuppressive doses of corticosteroids.

Measurements and Main Results – Twelve dogs were identified with the diagnosis of IMHA and severe thrombocytopenia; of these, 9 (75%) survived, 3 (25%) were euthanized, and none died. Dogs that survived were significantly younger than nonsurvivors (P=0.03). There were no specific clinical signs or therapies associated with survival.

Conclusions – Dogs in this study had a mortality rate similar to reported rates for dogs with either disease alone. Overall, younger dogs were more likely to survive. No association between different treatment modalities and overall survival was identified.

Ancillary